SPAC13G7.09c Antibody

What is SPAC13G7.09c and how is it characterized in S. pombe research?

SPAC13G7.09c is a protein-coding gene in Schizosaccharomyces pombe (fission yeast). Based on systematic genome analysis, this gene appears in multiple protein-protein interaction studies as evidenced by its inclusion in interaction networks . When studying this protein, researchers typically employ tagged versions for detection or generate specific antibodies against recombinant protein. Characterization often begins with genomic analysis followed by functional studies using deletion mutants or tagged versions integrated into the genome. The gene can be amplified from genomic DNA using PCR with specific primers designed to target the exact locus, similar to approaches used for other S. pombe genes . Successful characterization requires confirmation of expression through techniques such as Western blotting with appropriate antibodies.

What methods are recommended for generating SPAC13G7.09c-specific antibodies?

For generating specific antibodies against SPAC13G7.09c, researchers should consider the following methodology:

• Recombinant protein production: Clone the full SPAC13G7.09c coding sequence into a bacterial expression vector (like pET-30-a) using appropriate restriction sites (commonly BamHI and SalI) . Express the His-tagged protein in E. coli strains optimized for protein expression, such as BL21 or Tuner.

• Protein purification: Purify the recombinant protein using affinity chromatography such as the MagneHis Protein Purification System or Ni-NTA resin . Confirm purity via SDS-PAGE.

• Immunization strategy: Immunize rabbits for polyclonal antibodies using 250-500 μg of purified protein per injection with appropriate adjuvant, following a primary injection and 3-4 booster injections at 2-3 week intervals .

• Antibody purification: Extract serum and purify using protein A/G columns or antigen-specific affinity purification to improve specificity.

• Validation: Test antibody specificity using wild-type cells and knockout strains (Δspac13g7.09c) to confirm absence of signal in the deletion strain.

What are the optimal Western blot conditions for detecting SPAC13G7.09c in yeast lysates?

Optimal Western blot conditions for SPAC13G7.09c detection require careful sample preparation and protocol optimization:

• Cell lysis protocol: Harvest cells during exponential growth phase (OD595 < 0.4). Lyse cells using mechanical disruption with a FastPrep bead beater followed by boiling in sample buffer (2× Laemmli containing SDS and DTT) .

• Protein separation: Use 10% polyacrylamide gels for optimal resolution of SPAC13G7.09c, based on its predicted molecular weight.

• Transfer conditions: Transfer to nitrocellulose membrane at 100V for 1 hour or 30V overnight in standard Tris-glycine buffer with 20% methanol.

• Blocking solution: Block with 5% non-fat dry milk in TBST (TBS with 0.1% Tween-20) for 1 hour at room temperature.

• Antibody dilutions: Primary antibody (anti-SPAC13G7.09c) at 1:500-1:2000 dilution, incubated overnight at 4°C. Secondary HRP-conjugated antibody at 1:5000-1:10000 dilution for 1 hour at room temperature .

• Detection method: Visualize using enhanced chemiluminescence (ECL) with appropriate exposure times based on signal strength.

• Controls: Include β-actin (1:1000 dilution) as a loading control . For specificity control, include lysates from SPAC13G7.09c deletion strains.

How can researchers validate the specificity of SPAC13G7.09c antibodies?

Validation of SPAC13G7.09c antibodies requires multiple approaches to ensure specificity:

• Genetic validation: Compare Western blot signals between wild-type strains and SPAC13G7.09c deletion mutants . A specific antibody will show signal absence in the knockout strain.

• Epitope-tagged validation: Express SPAC13G7.09c with an epitope tag (HA, FLAG, or GFP) and perform parallel detection with both anti-SPAC13G7.09c and anti-tag antibodies. Co-localization of signals confirms specificity .

• Pre-absorption test: Pre-incubate the antibody with purified recombinant SPAC13G7.09c protein before immunodetection. Signal reduction indicates specificity.

• Cross-reactivity assessment: Test the antibody against closely related proteins or in other yeast species to evaluate potential cross-reactivity.

• Mass spectrometry validation: Perform immunoprecipitation followed by mass spectrometry to confirm the identity of the precipitated protein.

• Dilution series: Examine signal linearity across a dilution series of cell lysates to confirm proportional signal reduction.

How can SPAC13G7.09c antibodies be employed in protein-protein interaction studies?

SPAC13G7.09c antibodies can be strategically employed in protein-protein interaction studies through several methodological approaches:

• Co-immunoprecipitation (Co-IP): Use anti-SPAC13G7.09c antibodies conjugated to agarose or magnetic beads to pull down the protein complex from cell lysates. Analyze the precipitate by Western blot or mass spectrometry to identify interacting partners . For optimal results, use mild lysis conditions (non-ionic detergents like NP-40 or Triton X-100 at 0.5-1%) to preserve protein-protein interactions.

• Proximity ligation assay (PLA): Combine SPAC13G7.09c antibody with antibodies against suspected interaction partners, followed by PLA probes and detection reagents to visualize interactions in situ with cellular context preservation.

• Chromatin immunoprecipitation (ChIP): If SPAC13G7.09c has DNA-binding properties, use ChIP followed by sequencing or PCR to identify DNA regions associated with the protein and its interacting partners.

• Yeast two-hybrid validation: Use antibodies to confirm protein interactions identified through yeast two-hybrid screens by co-immunoprecipitation from native cellular contexts.

• Network analysis: Integrate antibody-derived interaction data with existing protein-protein interaction networks, similar to the approaches described in the YANA methodology, to build comprehensive interaction maps .

What strategies are recommended for immunofluorescence detection of SPAC13G7.09c?

For optimal immunofluorescence detection of SPAC13G7.09c in S. pombe, researchers should implement the following protocol:

• Cell fixation: Fix exponentially growing cells (OD595 < 0.4) with 3.7% formaldehyde for 30 minutes at room temperature, followed by cell wall digestion with Zymolyase (0.5 mg/ml) in PEMS buffer (100 mM PIPES, 1 mM EGTA, 1 mM MgSO4, 1.2 M Sorbitol, pH 6.9).

• Permeabilization: Permeabilize cells with 1% Triton X-100 in PBS for 2 minutes, followed by three washes with PBS containing 0.1% BSA.

• Blocking: Block with 5% normal goat serum in PBS with 0.1% BSA for 60 minutes.

• Primary antibody incubation: Incubate with anti-SPAC13G7.09c antibody (1:100-1:500 dilution) overnight at 4°C.

• Secondary antibody: Use fluorophore-conjugated secondary antibodies (1:500-1:1000) for 1 hour at room temperature. Select fluorophores that complement other cellular markers being used.

• Nuclear counterstaining: Stain nuclei with DAPI (1 μg/ml) for 5 minutes.

• Mounting and imaging: Mount cells in anti-fade reagent and image using confocal microscopy with appropriate filter sets.

• Controls: Include negative controls (primary antibody omission), deletion strain controls, and positive controls (epitope-tagged SPAC13G7.09c) with anti-tag antibodies .

How does SPAC13G7.09c expression change under different experimental conditions?

To characterize SPAC13G7.09c expression dynamics, researchers can implement quantitative approaches:

• Growth phase analysis: Monitor protein levels using Western blot across different growth phases (lag, exponential, stationary) by harvesting cells at specific OD595 values (0.1, 0.4, 1.0, 2.0) .

• Stress response: Expose cells to various stressors (oxidative stress with H2O2, heat shock at 42°C, nitrogen starvation) and analyze protein expression changes at designated time points (15, 30, 60, 120 minutes).

• Cell cycle synchronization: Synchronize cells using nitrogen starvation or hydroxyurea block, then release and collect samples at regular intervals to determine cell-cycle dependent expression.

• Quantitative analysis: Perform densitometric analysis of Western blots using ImageJ or similar software, normalizing to housekeeping proteins like β-actin .

• Transcriptional analysis: Complement protein studies with RT-qPCR or microarray analysis to correlate transcriptional and translational regulation.

*Hypothetical values based on typical stress response patterns in S. pombe; actual values would require experimental determination.

How can researchers address non-specific binding issues with SPAC13G7.09c antibodies?

Non-specific binding is a common challenge with yeast protein antibodies. Implement these strategies to improve specificity:

• Antibody purification: Perform affinity purification of the antibody using recombinant SPAC13G7.09c protein immobilized on an appropriate matrix. This significantly reduces cross-reactivity by enriching for antibodies that specifically recognize the target protein.

• Blocking optimization: Test different blocking agents (5% BSA, 5% non-fat milk, commercial blocking buffers) to identify the optimal formulation that minimizes background without compromising specific signal.

• Antibody dilution optimization: Perform a dilution series (1:250 to 1:5000) to identify the optimal concentration that provides sufficient specific signal while minimizing background.

• Wash stringency: Increase the number of washes (5-6 times) and/or add detergent (0.1-0.3% Tween-20 or 0.05-0.1% SDS) to washing buffers to reduce non-specific binding.

• Pre-absorption strategy: Pre-incubate the antibody with lysates from SPAC13G7.09c deletion strains to remove antibodies that bind to other yeast proteins .

• Competition assays: Include varying amounts of purified recombinant SPAC13G7.09c protein during antibody incubation to demonstrate signal specificity through competitive inhibition.

• Cross-linking: If performing immunoprecipitation, optimize cross-linking conditions (0.5-3% formaldehyde for 5-15 minutes) to stabilize protein complexes while minimizing non-specific aggregation.

What are the best practices for long-term storage of SPAC13G7.09c antibodies?

To maintain antibody activity during long-term storage, follow these methodological guidelines:

• Storage temperature: Store antibody aliquots at -80°C for long-term storage and at -20°C for working aliquots. Avoid repeated freeze-thaw cycles by preparing appropriately sized single-use aliquots.

• Buffer composition: Store in phosphate-buffered saline (PBS, pH 7.4) containing 30-50% glycerol, 1% BSA, and 0.02-0.05% sodium azide as a preservative.

• Aliquot preparation: Divide the antibody solution into 10-50 μl aliquots in low-protein-binding microcentrifuge tubes to minimize freeze-thaw cycles.

• Documentation: Label each aliquot with concentration, date prepared, and lot number. Maintain a usage log to track antibody performance over time.

• Stability testing: Periodically test stored antibodies against fresh positive controls to monitor potential activity loss.

• Lyophilization option: For very long-term storage (>2 years), consider lyophilization with appropriate cryoprotectants followed by storage at -20°C with desiccant.

• Recovery optimization: When thawing, warm to room temperature slowly and mix gently by inversion rather than vortexing to preserve antibody integrity.

How can SPAC13G7.09c antibodies be used in chromatin immunoprecipitation (ChIP) studies?

For successful application of SPAC13G7.09c antibodies in ChIP studies, follow this optimized protocol:

• Crosslinking: Crosslink S. pombe cells during exponential growth (OD595 0.4-0.6) with 1% formaldehyde for 15 minutes at room temperature, then quench with 125mM glycine.

• Cell lysis: Lyse cells mechanically using glass beads in a FastPrep device (setting 6.0, 3 × 30 seconds) . Ensure efficient cell wall disruption by microscopic examination.

• Chromatin shearing: Sonicate lysates to generate DNA fragments of 200-500bp (typically 15-25 cycles of 30 seconds on/30 seconds off using a Bioruptor or similar device).

• Pre-clearing: Pre-clear chromatin with Protein A/G beads for 1 hour at 4°C to reduce non-specific binding.

• Immunoprecipitation: Incubate pre-cleared chromatin with anti-SPAC13G7.09c antibody (3-5 μg) overnight at 4°C with rotation, followed by addition of Protein A/G beads for 2-3 hours.

• Washing: Perform stringent washing steps (low salt, high salt, LiCl, and TE buffers) to remove non-specifically bound material.

• Elution and reversal: Elute protein-DNA complexes and reverse crosslinks by heating at 65°C overnight in the presence of proteinase K.

• DNA purification: Purify DNA using phenol-chloroform extraction or commercial kits for downstream analysis (qPCR or sequencing).

• Controls: Include input DNA (non-immunoprecipitated), IgG control, and samples from SPAC13G7.09c deletion strains as negative controls .

How can researchers quantitatively compare results from different lots of SPAC13G7.09c antibodies?

To ensure reproducibility when transitioning between antibody lots, implement this standardized comparison methodology:

• Standard curve generation: Create a dilution series of recombinant SPAC13G7.09c protein (5-500 ng) and perform Western blots with both antibody lots under identical conditions.

• Signal calibration: Plot signal intensity vs. protein amount for each antibody lot and determine the linear detection range.

• Normalization factor calculation: Calculate the ratio of signals between old and new lots at multiple points within the linear range to establish a conversion factor.

• Reference sample library: Maintain frozen aliquots of standard lysates from wild-type cells as reference samples for inter-lot calibration.

• Cross-validation experiment: Perform side-by-side testing of both antibody lots on identical samples from key experimental conditions.

• Statistical analysis: Calculate correlation coefficients between results from different lots and determine whether systematic correction factors need to be applied.

• Internal controls: Always include an internal normalization protein (β-actin, tubulin) that's detected with a consistent antibody across experiments .

How can SPAC13G7.09c antibodies be integrated with mass spectrometry approaches?

Combining immunodetection with mass spectrometry offers powerful insights through these methodological approaches:

• Immunoprecipitation-mass spectrometry (IP-MS): Use anti-SPAC13G7.09c antibodies to pull down the protein and its interacting partners, followed by tryptic digestion and LC-MS/MS analysis to identify components of the protein complex.

• Quantitative proteomics: Combine antibody-based enrichment with SILAC, iTRAQ, or TMT labeling to quantitatively compare SPAC13G7.09c-associated proteins under different conditions.

• Cross-linking MS: Implement protein cross-linking prior to immunoprecipitation to capture transient interactions, followed by MS analysis to map interaction interfaces within protein complexes.

• Selected reaction monitoring (SRM): Develop SRM assays targeting specific SPAC13G7.09c peptides for sensitive and specific quantification across experimental conditions.

• Post-translational modification mapping: Use antibody enrichment followed by MS to identify and quantify post-translational modifications on SPAC13G7.09c under different cellular conditions.

• Data integration: Combine immunoprecipitation-MS results with yeast network analysis approaches like YANA to position SPAC13G7.09c within the broader protein interaction network context .

What considerations are important when designing experiments with SPAC13G7.09c antibodies in genetic screens?

When integrating SPAC13G7.09c antibodies into genetic screen workflows, consider these methodological factors:

• Genetic background selection: Use appropriate genetic backgrounds (wild-type, specific mutants) and ensure the deletion library strain collection is compatible with your screening approach .

• Epitope tagging strategy: If tagging SPAC13G7.09c, consider tag position (N- or C-terminal) and confirm tag doesn't interfere with protein function through complementation tests.

• Expression system selection: Choose between native promoter expression or regulated systems (nmt1 promoter with thiamine control) based on experimental requirements .

• High-throughput adaptations: Optimize antibody-based detection for multi-well format (384 or 1536) compatible with robotic liquid handling systems used in large-scale screens .

• Quantification methods: Implement automated image analysis algorithms for consistent quantification of immunofluorescence or Western blot signals across numerous samples.

• Validation strategy: Design a tiered validation approach where initial hits from screens are confirmed with secondary assays using the same antibodies under more stringent conditions.

• Statistical analysis: Apply appropriate statistical methods for hit identification that account for plate-to-plate variation in antibody performance.